CytomX Therapeutics, Inc. (NASDAQ:CTMX) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. trimmed its holdings in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 63.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 599,850 shares of the biotechnology company's stock after selling 1,044,318 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.77% of CytomX Therapeutics worth $618,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. US Bancorp DE purchased a new position in CytomX Therapeutics in the third quarter worth $40,000. XTX Topco Ltd grew its holdings in CytomX Therapeutics by 382.6% in the second quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company's stock worth $74,000 after purchasing an additional 48,033 shares during the last quarter. Forefront Analytics LLC grew its holdings in CytomX Therapeutics by 206.7% in the second quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company's stock worth $78,000 after purchasing an additional 43,176 shares during the last quarter. Cubist Systematic Strategies LLC grew its holdings in shares of CytomX Therapeutics by 96.6% during the second quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company's stock valued at $100,000 after buying an additional 40,309 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of CytomX Therapeutics during the third quarter valued at $104,000. 67.77% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a "neutral" rating on shares of CytomX Therapeutics in a report on Tuesday, January 7th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $5.77.

CytomX Therapeutics Stock Up 2.7 %

Shares of CTMX traded up $0.02 during trading hours on Friday, reaching $0.89. 672,457 shares of the company traded hands, compared to its average volume of 983,236. The stock has a market capitalization of $69.74 million, a P/E ratio of 5.24 and a beta of 1.03. The business has a fifty day moving average price of $1.02 and a 200-day moving average price of $1.14. CytomX Therapeutics, Inc. has a 12-month low of $0.79 and a 12-month high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last posted its earnings results on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.23. The company had revenue of $33.43 million during the quarter, compared to the consensus estimate of $18.92 million. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. During the same period in the previous year, the firm posted $0.04 earnings per share. As a group, research analysts predict that CytomX Therapeutics, Inc. will post -0.05 EPS for the current fiscal year.

CytomX Therapeutics Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.